ECSP20039728A - Anticuerpos monoclonales y métodos para utilizar los mismos - Google Patents
Anticuerpos monoclonales y métodos para utilizar los mismosInfo
- Publication number
- ECSP20039728A ECSP20039728A ECSENADI202039728A ECDI202039728A ECSP20039728A EC SP20039728 A ECSP20039728 A EC SP20039728A EC SENADI202039728 A ECSENADI202039728 A EC SENADI202039728A EC DI202039728 A ECDI202039728 A EC DI202039728A EC SP20039728 A ECSP20039728 A EC SP20039728A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibody
- family
- monoclonal antibodies
- cells
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención se relaciona con anticuerpos monoclonales que se unen de manera específica a la familia TRBV9 del receptor de las células T humanas. La invención también se relaciona con un ácido nucleico que codifica el anticuerpo o con un fragmento que se une al antígeno del mismo, a un vector de expresión, con un método para producir el anticuerpo, y con el uso del anticuerpo para tratar las enfermedades o trastornos asociados con la familia del receptor de las células T humanas. La invención está dirigida hacia la producción de anticuerpos que pueden utilizarse para eliminar las células T que portan los receptores de las células T de la familia TRBV9, en particular, para tratar la espondilitis anquilosante, la enfermedad celiaca y los cánceres de la sangre, en la patogénesis de las cuales, están involucrados los receptores de las células T de la familia TRBV9.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2017145662A RU2694412C9 (ru) | 2017-12-25 | 2017-12-25 | Моноклональные антитела и способы их применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20039728A true ECSP20039728A (es) | 2020-08-31 |
Family
ID=67002533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202039728A ECSP20039728A (es) | 2017-12-25 | 2020-07-13 | Anticuerpos monoclonales y métodos para utilizar los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11597767B2 (es) |
| EP (1) | EP3733705A4 (es) |
| JP (1) | JP7339948B2 (es) |
| KR (1) | KR102867660B1 (es) |
| CN (1) | CN111801354B (es) |
| AU (1) | AU2018398341B2 (es) |
| BR (1) | BR112020012959A2 (es) |
| CA (1) | CA3086849A1 (es) |
| CL (1) | CL2020001726A1 (es) |
| CR (1) | CR20200324A (es) |
| EA (1) | EA202091569A1 (es) |
| EC (1) | ECSP20039728A (es) |
| JO (1) | JOP20200161B1 (es) |
| MA (1) | MA50128B1 (es) |
| MX (1) | MX2020006736A (es) |
| NI (1) | NI202000051A (es) |
| PE (1) | PE20200927A1 (es) |
| PH (1) | PH12020551012A1 (es) |
| RU (1) | RU2694412C9 (es) |
| WO (1) | WO2019132738A1 (es) |
| ZA (1) | ZA202003858B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2694412C9 (ru) * | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| RU2712251C1 (ru) | 2018-12-25 | 2020-01-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
| AR117735A1 (es) * | 2018-12-25 | 2021-08-25 | Joint Stock Company Biocad | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO |
| CN114127112A (zh) * | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| EP3927744A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| UY40402A (es) * | 2022-08-18 | 2024-03-15 | Biocad Joint Stock Co | Método de tratamiento de enfermedad o trastorno mediado por linfocitos t que portan el segmento trbv |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766947A (en) | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| US5223426A (en) | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| RU2539032C2 (ru) | 2009-06-25 | 2015-01-10 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ измерения искусственного иммунитета |
| EP3202784A1 (en) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | T-cell receptor sequences for active immunotherapy |
| JP6952225B2 (ja) * | 2016-03-18 | 2021-10-20 | 北海道公立大学法人 札幌医科大学 | Ｔ細胞レセプターとその利用 |
| CN109715669B (zh) | 2016-06-17 | 2023-01-24 | 基因医疗免疫疗法股份有限公司 | T细胞受体及其用途 |
| RU2694412C9 (ru) * | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
| RU2712251C1 (ru) | 2018-12-25 | 2020-01-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
| AR117735A1 (es) | 2018-12-25 | 2021-08-25 | Joint Stock Company Biocad | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO |
-
2017
- 2017-12-25 RU RU2017145662A patent/RU2694412C9/ru active
-
2018
- 2018-12-25 CA CA3086849A patent/CA3086849A1/en active Pending
- 2018-12-25 MA MA50128A patent/MA50128B1/fr unknown
- 2018-12-25 AU AU2018398341A patent/AU2018398341B2/en active Active
- 2018-12-25 KR KR1020207021655A patent/KR102867660B1/ko active Active
- 2018-12-25 CR CR20200324A patent/CR20200324A/es unknown
- 2018-12-25 US US16/957,328 patent/US11597767B2/en active Active
- 2018-12-25 MX MX2020006736A patent/MX2020006736A/es unknown
- 2018-12-25 WO PCT/RU2018/050168 patent/WO2019132738A1/ru not_active Ceased
- 2018-12-25 CN CN201880090210.0A patent/CN111801354B/zh active Active
- 2018-12-25 PE PE2020000858A patent/PE20200927A1/es unknown
- 2018-12-25 EP EP18895626.2A patent/EP3733705A4/en active Pending
- 2018-12-25 EA EA202091569A patent/EA202091569A1/ru unknown
- 2018-12-25 BR BR112020012959-3A patent/BR112020012959A2/pt unknown
- 2018-12-25 JP JP2020535637A patent/JP7339948B2/ja active Active
-
2020
- 2020-06-24 CL CL2020001726A patent/CL2020001726A1/es unknown
- 2020-06-25 JO JOJO/P/2020/0161A patent/JOP20200161B1/ar active
- 2020-06-25 PH PH12020551012A patent/PH12020551012A1/en unknown
- 2020-06-25 NI NI202000051A patent/NI202000051A/es unknown
- 2020-06-25 ZA ZA2020/03858A patent/ZA202003858B/en unknown
- 2020-07-13 EC ECSENADI202039728A patent/ECSP20039728A/es unknown
-
2023
- 2023-01-30 US US18/103,194 patent/US12514923B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20039728A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos | |
| CO2021009689A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| CL2021001704A1 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| CL2020000452A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| MX2016008472A (es) | Anticuero monoclonal neutralizador de anti-il-33-humana. | |
| MX2018013548A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| MX2020013122A (es) | Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47). | |
| MX2018004531A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| MX2017011534A (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| MX2019011520A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| CL2021002792A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| BR112022009611A2 (pt) | Anticorpos anti-ror-2 e métodos de uso | |
| CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| AR133072A2 (es) | Anticuerpos aislados o fragmentos aislados de unión a antígeno de los mismos que se unen al receptor de leptina humana (lepr) y activan la señalización lepr | |
| AR106198A1 (es) | Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3) |